Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint

Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint

Seattle enters second ADC research collaboration agreement with Genmab

Seattle enters second ADC research collaboration agreement with Genmab

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma

NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

Celldex presents CDX-1127 preclinical data against cancer at AACR meeting

Celldex presents CDX-1127 preclinical data against cancer at AACR meeting

NIAID awards Aragen Bioscience with three subcontracts to advance preclinical studies

NIAID awards Aragen Bioscience with three subcontracts to advance preclinical studies

Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting

Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting

New research finds HIV virus's V3 loop as attractive vaccine target

New research finds HIV virus's V3 loop as attractive vaccine target

Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck submits Erbitux indication extension to EMA for NSCLC treatment

AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting

AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting

U.S. FDA approves Yervoy to treat patients with late-stage melanoma

U.S. FDA approves Yervoy to treat patients with late-stage melanoma

FDA approves ipilimumab for metastatic melanoma treatment

FDA approves ipilimumab for metastatic melanoma treatment

BMY receives FDA approval for YERVOY to treat metastatic melanoma

BMY receives FDA approval for YERVOY to treat metastatic melanoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.